Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-IFN alfa-2b alone versus PEG-IFN alfa-2b + adefovir in HBeAg-positive chronic hepatitis B
ChiCTR-TRC-12002226Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital, Anhui Medical University
- Start
- May 2012
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b and adefovir dipivoxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by The First Affiliated Hospital, Anhui Medical University. Primary endpoints: Serum HBsAg quantitation, Serum HBeAg quantitation and 8 more. Started May 2012; status: recruiting.
02
Drugs
peginterferon alfa-2badefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on ChiCTR-TRC-12002226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002226.